OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Germany; German Cancer Consortium (DKTK), partner site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Germany; German Cancer Consortium (DKTK), partner site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Radiother Oncol. 2019 Jan;130:164-171. doi: 10.1016/j.radonc.2018.06.036. Epub 2018 Jul 20.
The limited availability of proton beam therapy (PBT) requires individual treatment selection strategies, such as based on normal tissue complication probability (NTCP). We developed and externally validated NTCP models for common acute side-effects following PBT in brain tumour patients in effort to provide guidance on optimising patient quality of life.
An exploration cohort including 113 adult brain tumour patients who underwent PBT was investigated for the following endpoints: alopecia, scalp erythema, headache, fatigue and nausea. Dose-volume parameters of associated normal tissues were used for logistic regression modelling. Statistically significant parameters showing high area under the receiver operating characteristic curve (AUC) values in internal cross-validation were externally validated on two cohorts of 71 and 96 patients, respectively.
Statistically significant correlations of dose-volume parameters of the skin for erythema and alopecia were found. In internal cross-validation, the following prognostic parameters were selected: V35Gy (absolute volume receiving 35 Gy) for erythema grade ≥1, D2% (dose to 2% of the volume) for alopecia grade ≥1 and D5% for alopecia grade ≥2. Validation was successful for both cohorts with AUC >0.75. A bivariable model for fatigue grade ≥1 could not be validated externally. No correlations of dose-volume parameters of the brain were seen for headache or nausea.
We developed and successfully validated NTCP models for scalp erythema and alopecia in primary brain tumour patients treated with PBT.
质子束治疗(PBT)的应用有限,需要制定个体化的治疗选择策略,例如基于正常组织并发症概率(NTCP)。我们开发并验证了 PBT 治疗脑肿瘤患者常见急性不良反应的 NTCP 模型,旨在为优化患者生活质量提供指导。
我们研究了 113 例接受 PBT 的成人脑肿瘤患者,以评估以下终点:脱发、头皮红斑、头痛、疲劳和恶心。使用相关正常组织的剂量-体积参数进行逻辑回归建模。内部交叉验证中具有高受试者工作特征曲线(ROC)曲线下面积(AUC)值的显著参数在分别对 71 例和 96 例患者的两个队列进行了外部验证。
皮肤的剂量-体积参数与红斑和脱发之间存在显著的相关性。内部交叉验证中,选择了以下预后参数:V35Gy(接受 35Gy 的绝对体积)用于红斑≥1 级,D2%(2%体积的剂量)用于脱发≥1 级,D5%用于脱发≥2 级。两个队列的 AUC 均大于 0.75,验证均成功。外部验证无法验证疲劳≥1 级的双变量模型。脑的剂量-体积参数与头痛或恶心之间无相关性。
我们开发并成功验证了 PBT 治疗原发性脑肿瘤患者头皮红斑和脱发的 NTCP 模型。